tirzepatide homekit Lab Test – Healthogenics Tirzepatide (Month 1) 2.5mg |

Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (under the brand name Mounjaro), chronic weight management (under the brand name Zepbound), and most recently in 2024, for the treatment of adults with moderate-to-severe obstructive sleep apnea who have obesity or are overweight with at least one weight-related comorbidity

The reported reduced alcohol consumption may also be linked to changes in appetite

Integrated Metabolic Signaling The simultaneous activation of all three receptor systems creates a coordinated metabolic response that extends beyond the individual effects of each pathway

Cora Health typically approves eligible patients within 24 hours of assessment submission, and medications ship via free expedited delivery from Hallandale Pharmacy or VialsRx